These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27154025)

  • 1. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
    Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
    J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
    Launay-Vacher V; Deray G
    Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
    Roodhart JM; Langenberg MH; Witteveen E; Voest EE
    Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
    Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
    Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma.
    Lai S; Molfino A; Seminara P; Longo F; Innico G; Coppola B; Mastroluca D; Galani A; Dimko M; Aceto P; Lai C
    Curr Vasc Pharmacol; 2018 Jan; 16(2):190-196. PubMed ID: 28676023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
    Izzedine H
    Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
    Tesařová P; Tesař V
    Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.
    Ko HT; Yin JL; Wyburn K; Wu H; Eris JM; Hambly BD; Chadban SJ
    Nephrol Dial Transplant; 2013 Feb; 28(2):327-36. PubMed ID: 23229928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
    Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
    Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
    Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
    Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinuria and VEGF-targeted therapies: 
an underestimated toxicity?
    Izzedine H; Soria JC; Escudier B
    J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.
    Zhang C; Wang N; Tan HY; Guo W; Li S; Feng Y
    Integr Cancer Ther; 2018 Sep; 17(3):582-601. PubMed ID: 29807443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
    Vigneau C; Rioux-Leclercq N
    Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA; Verweij J
    Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticancer drugs under pressure].
    Ben Aïssa A; George AC; El M'Rabet FZ; Mach N; Dietrich PY; Pechère-Bertschi A
    Rev Med Suisse; 2011 Sep; 7(308):1761-6. PubMed ID: 21954818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF signal system: the application of antiangiogenesis.
    Liang X; Xu F; Li X; Ma C; Zhang Y; Xu W
    Curr Med Chem; 2014 Mar; 21(7):894-910. PubMed ID: 24059233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
    Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.